TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13624-13636

  Chlapanidas, Theodora ^a   Perteghella, Sara ^a   Leoni, Flavio ^b   Faragò, Silvio ^c   Marazzi, Mario ^d   Rossi, Daniela ^a   Martino, Emanuela ^a   Gaggeri, Raffaella ^a   Collina, Simona ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Italfarmaco SpA   (Italy)

^c Innovhub Stazioni Sperimentali per l'Industria Divisione Seta ^*  (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Anti inflammatory activity; Flavanones; Microparticles; Naringenin; Psoriasis; Sericin; TNF

Indexed keywords

DRUG CARRIER; MICROPARTICLE; MICROSPHERE; NARINGENIN; SERICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; FLAVANONE DERIVATIVE; LIPOPOLYSACCHARIDE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PSORIASIS; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; MEDICINAL CHEMISTRY; METABOLISM; MONONUCLEAR CELL;

CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DOWN-REGULATION; FLAVANONES; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICROSPHERES; PARTICLE SIZE; PSORIASIS; SERICINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925243024     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813624     Document Type: Article

References (14)

1. Gaggeri, R.; Rossi, D.; Hajikarimian, N.; Martino, E.; Bracco, F.; Grisoli, P.; Dacarro, C.; Leoni, F.; Mascheroni, G.; Collina, S.; et al. Preliminary study on TNFα-blocker activity of amygdalus lycioides spach extracts. Open Nat. Prod. J. 2010, 3, 20-25.
2. Gaggeri, R.; Rossi, D.; Christodoulou, M.S.; Passerella, D.; Leoni, F.; Azzolina, O.; Collina, S. Chiral flavanones from amygdalus lycioides spach: Structural elucidation and identification of TNFα inhibitors by bioactivity-guided fractionation. Molecules 2012, 17, 1665-1674.
3. Gaggeri, R.; Rossi, D.; Daglia, M.; Leoni, F.; Avanzini, M.A.; Mantelli, M.; Juza, M.; Collina, S. An ecofriendly enantioselective access to (R)-Naringenin as inhibitor of pro-inflammatory cytokines release. Chem. Biodivers. 2013, 10, 1532-1538.
4. Padamwar, M.N.; Pawar, A.P. Silk sericin and its applications: A review. J. Sci. Ind. Res. 2004, 63, 323-329.
5. Chlapanidas, T.; Faragò, S.; Lucconi, G.; Perteghella, S.; Galuzzi, M.; Mantelli, M.; Avanzini, M.A.; Tosca, M.C.; Marazzi, M.; Vigo, D.; et al. Sericins exhibit ROS-scavenging, anti-tyrosinase, anti-elastase, and in vitro immunomodulatory activities. Int. J. Biol. Macromol. 2013, 58, 47-56.
6. Prieto-Pérez, P.; Cabaleiro, T.; Daudén, E.; Ochoa, M.; Roman, M.; Abad-Santos, F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmun. Dis. 2013, 2013, 613086.
7. Traub, M.; Marshall, K. Psoriasis-Pathophysiology, conventional, and alternative approaches to treatment. Altern. Med. Rev. 2007, 12, 319-330.
8. Nograles, K.E.; Krueger, J.G. Anti-cytokine therapies for psoriasis. Exp. Cell Res. 2011, 317, 1293-1300.
9. Bos, J.D.; Spuls, P.I. Topical treatments in psoriasis: Today and tomorrow. Clin. Dermatol. 2008, 26, 432-437.
10. Laws, P.M.; Young, H.S. Current and emerging systemic treatment strategies for psoriasis. Drugs 2012, 72, 1867-1880.
11. Kupetsky, E.A.; Mathers, A.R.; Ferris, L.K. Anti-cytokine therapy in the treatment of psoriasis. Cytokine 2013, 61, 704-712.
12. Oh, H.; Kim, M.K.; Lee, K.H. Preparation of sericin microparticles by electrohydrodynamic spraying and their application in drug delivery. Macromol. Res. 2011, 19, 266-272.
13. Leoni, F.; Fossati, G.; Lewis, E.C.; Lee, J.K.; Porro, G.; Pagani, P.; Modena, D.; Moras, M.L.; Pozzi, P.; Reznikov, L.L.; et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11, 1-15.
14. Padamwar, M.N.; Pawar, A.P.; Daithankar, A.V.; Mahadik, K.R. Silk sericin as a moisturizer: An in vivo study. J. Cosmet. Dermatol. 2005, 4, 250-257.